Skip to main content
NIH funding notice PAR-18-829

NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33 Clinical Trial Required)

Closed on November 4, 2019.

Posted
June 13, 2018
Close date
November 4, 2019
Activity codes
R61, R33
Institutes taking part
ODS

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

  1. Reissues: PAR-17-319 NCCIH Natural Product Phase I-IIa Clinical Trial Phased Innovation Award (R61/R33)
  2. 2 steps back: PAR-16-418 Exploratory Clinical Trials and Studies of Natural Products in NCCIH High Priority Research Topics (R61/R33)
  3. 3 steps back: RFA-AT-16-001 Phased Innovation Award for Exploratory Clinical Trials of Natural Products in NCCIH High Priority Research Topics (R21/R33)

Replaced by PAR-20-218.

Who won it before

13 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $3,785,235 in first-year total cost, median $311,595.

Most frequent study sections

  1. Special Emphasis Panel[ZAT1 VS (08)]6
  2. Special Emphasis Panel[ZAT1 SM (38)]3
  3. Special Emphasis Panel[ZAT1 YW (01)]2
  4. Special Emphasis Panel[ZAT1 SM (45)]1
  5. Special Emphasis Panel[ZAT1 SM (54)]1

Most frequent institutions

  1. BAYLOR COLLEGE OF MEDICINE1
  2. CASE WESTERN RESERVE UNIVERSITY1
  3. COLUMBIA UNIVERSITY HEALTH SCIENCES1
  4. GEORGETOWN UNIVERSITY1
  5. OREGON HEALTH & SCIENCE UNIVERSITY1
Competing awards under PAR-18-829 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
202031P-MRS and resting state functional connectivity analysis of the effects of 5-hydroxytryptophan and creatine for antidepressant augmentation in patients with SSRI/SNRI-resistant major depressive diso1R61AT010636-01A1KIOUS, BRENT MICHAELRENSHAW, PERRY FRANKLINUNIVERSITY OF UTAH, UT$381,055ZAT1
2019A phased clinical trial of a dietary supplement kava: biomarker changes and anxiolytic effects1R61AT009988-01A1MATHEWS, CAROL AXING, CHENGGUOUNIVERSITY OF FLORIDA, FL$378,341ZAT1
2018Exploratory Pilot Studies to Demonstrate Mechanisms of Preventing Antibiotic-Associated Diarrhea and the Role for Probiotics1R61AT009622-01A1 · under PAR-17-319FRASER, CLAIRE M.MERENSTEIN, DANIEL JGEORGETOWN UNIVERSITY, DC$392,910ZAT1
2018Development of Pregnenolone as a Treatment for Depression1R61AT009625-01A1 · under PAR-17-319BROWN, E SHERWOODUT SOUTHWESTERN MEDICAL CENTER, TX$336,791ZAT1
2018Ginger's therapeutic potential in asthma1R61AT009989-01 · under PAR-17-319DIMANGO, EMILYEMALA, CHARLES WCOLUMBIA UNIVERSITY HEALTH SCIENCES, NY$332,175ZAT1
2018Impact of quercetin on inflammatory and oxidative stress markers in COPD1R61AT009991-01 · under PAR-17-319MARCHETTI, NATHANIELSAJJAN, UMADEVI SIVANAPPATEMPLE UNIV OF THE COMMONWEALTH, PA$311,595ZAT1
2018Prebiotic Treatment in People with Schizophrenia1R61AT009990-01 · under PAR-17-319BUCHANAN, ROBERT WUNIVERSITY OF MARYLAND BALTIMORE, MD$308,878ZAT1
2018Identifying Biological Signatures of N-acetylcysteine for Non-Suicidal Self-Injury in Adolescents1R61AT009995-01 · under PAR-17-319CULLEN, KATHRYN REGANUNIVERSITY OF MINNESOTA, MN$307,912ZAT1
2017Fatty acid supplements alter biological signatures in children with Autism Spectrum Disorder1R61AT009632-01 · under PAR-16-418KEIM, SARAHROGERS, LYNETTE KAYRESEARCH INST NATIONWIDE CHILDREN'S HOSP, OH$327,066ZAT1
2017Biological signatures of the cognitive effects of Centella asiatica1R61AT009628-01 · under PAR-16-418QUINN, JOSEPH FSOUMYANATH, AMALAOREGON HEALTH & SCIENCE UNIVERSITY, OR$73,000ZAT1
2016Role of Zinc in HIV inflammation1R21AT009153-01 · under RFA-AT-16-001MCCOMSEY, GRACE ACASE WESTERN RESERVE UNIVERSITY, OH$226,110ZAT1
2016Peppermint Oil Pharmacokinetics/Dynamics and Novel Biological Signatures in Children with Functional Abdominal Pain1R21AT009101-01 · under RFA-AT-16-001SHULMAN, ROBERT JBAYLOR COLLEGE OF MEDICINE, TX$218,158ZAT1
2016Phased Exploratory Clinical Studies of Harpagophytum procumbens’ Impact upon the Biological Signature of Inflammatory Osteoarthritis1R21AT009086-01 · under RFA-AT-16-001FOLK, WILLIAM ROBERTGERKOVICH, MARY M.UNIVERSITY OF MISSOURI KANSAS CITY, MO$191,244ZAT1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.

PAR-18-829: NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33 Clinical Trial Required) | ScienceDex | ConductScience